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Abstract - Theranostic micelles and polymeric nanocarrier-based drug delivery system are well known 
techniques that involve a diagnostic agent in polymeric micelles for a combination of therapy by using a co-
delivery approach which can help in detection of a cancer cell in an early stage, increase killing effect and 
suppress multi-drug resistance (MDS) for better therapeutic effectiveness. The aim of this study is to develop 
a dual modality micellar system using D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) as a 
nanocarrier for co-delivery of docetaxel as a model chemotherapeutic drug and coumarin-6 as a model 
fluorescence imaging agent for simultaneous cancer imaging and therapy in an early stage. The theranostic 
micelles were prepared by a solvent casting method and characterized by their particle size, drug loading, 
drug encapsulation efficiency (EE) and in-vitro drug release profile. These dual modality micellar system 
TPDC6 micelles were successfully developed with average particle size of 79.59±0.57 nm in diameter and 
drug loading up to 15.46±1.02 % (EE of 78.99±1.26%) and 9.83±0.76 % (EE of 36.20±0.89%) for docetaxel 
and coumarin-6 respectively. Besides, the in-vitro drug release profile of the micelles revealed a desired 
sustained and controlled drug release manner for both docetaxel (21.62±0.36%) and coumarin-6 
(10.70±0.46%). In conclusion, the micelles size obtained is in the favourable range for passive targeting 
through enhanced permeability and retention (EPR) effect and the drug loading and encapsulation efficiency 
attained are adequate for therapy and diagnosis purposes on cancer cells. This dual modality system is taking 
great advantages for tumour imaging and inhibition of tumour growth which is very important for early 
cancer detection. 
 
Indexed Terms- Nanomedicine; Polymeric micelle; Docetaxel; Coumarin-6, Biomaterial, 
Chemotherapeutic  
 
I. INTRODUCTION 
 
Cancer is commonly characterized by uncontrolled cell growth caused by up-regulation of 
oncogenes or down-regulation of tumour suppressor genes and angiogenesis [1]. It is also one the 
leading causes of death overall the world. Molecular subtypes of breast cancer include luminal A, 
luminal B, basal-like breast cancer, triple negative breast cancer (TNBC) and epidermal growth 
factor receptor 2 HER2-positive breast cancer [2]. Breast cancer is classified based on tumour 
markers of progesterone receptor (PR), estrogen receptor (ER) and HER2 [3]. However, TNBC 
lack of these three receptor proteins (PR
- 
/ ER
- 
/ HER2
-
). The incidence of TNBC cases in Malaysia 
is approximately 17%, a rate similar to that found in Western studies [4]. Treatment options 
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currently available for TNBC are limited to standard cytotoxicity chemotherapy such as paclitaxel 
due to the lack of therapeutic target required to effectively deliver drugs to the tumour with a 
minimal side effect on healthy cells and multidrug resistance (MDR) exhibited by a cancer tumour 
that prevents delivery of therapeutic agents into tumours [5,6]. However, nanomedicine offers 
effective solutions to overcome the problems encountered by conventional chemotherapy. 
Nanomedicines are able to deliver therapeutic agents into the targeted cells via receptor-mediated 
endocytosis (RME). Further,  nanomedicines are also capable of conquering MDR by providing 
protection to therapeutic agents and prevent elimination of P-glycoproteins (P-gp) [7]. Issues with 
conventional chemotherapy such as drug resistance, formulation and pharmacokinetics (controlled 
drug release) may be solved with the assist of nanomedicine.  
Patients with TNBC are usually detected at the late stages, have an aggressive tumour type 
due to the high rate of local recurrences and systematic metastases and a poorer prognosis 
compared to patients with non-TNBC [8]. In addition, the mean time to local and distant 
recurrence was shorter in patients with TNBC than other cancers which were 2.8 versus 4.2 years 
and 2.6 versus 5.0 years respectively [9]. These patients were significantly more likely to have 
visceral metastases, which might contribute to their poorer prognosis. Hence, there is a clear 
demand to examine nanotheranostics for sensitive diagnosis at its earliest stage and can effectively 
use in the treatment of TNBC a tumour by the therapeutic agent. 
The aim of this study is to develop and characterize a novel theranostic micelle system for 
cancer treatment in addition to study the drug release profile of the micellar system. The scopes of 
study are to synthesize the dual-modality system of docetaxel-coumarin-6-loaded vitamin E TPGS 
micelles (TPDC6) and optimize it to achieve desired particle size, drug loading and precise drug 
release in pH 7.4. Docetaxel is chosen as the model anticancer agent or therapeutic agent whereas 
coumarin-6 is chosen as the diagnostics or imaging agent and both are encapsulated by TPGS 
which serve as their nanocarriers into TNBC cells. Docetaxel leads to a mitotic arrest in the G2/M 
phase of the cell cycle by binding to microtubules and causes cell death [7]. Coumarin-6 with 
fluorescence property is able to act as a fluorescent probe for applications such as biomarker and 
bioimaging to visualize morphological details and monitor biomolecule in living systems [10]. 
Vitamin E consisting of a lipophilic alkyl tail and a hydrophilic polar head was used to synthesize 
the polymeric micelle which above its critical micelle concentration (CMC) of 0.02 wt%. The co-
delivery of both chemotherapeutic agent and diagnosis agent in a dual drug micelle system form a 
theranostic nanoparticle that can be used in the diagnosis and therapy of breast cancer in an early 
stage which can control local recurrences and prevent distant metastases [11]. 
 
1.1 Materials  
Docetaxel (anhydrous, 99.56% purity), Coumarin-6 and Vitamin E TPGS (D-α-tocopheryl 
polyethylene glycol 1000 succinate, C33O5H54(CH2CH2O)23) were obtained from the National 
University of Singapore (NUS). Chloroform (stabilised with 0.6-1.0% ethanol) was purchased 
from R&M Chemicals. Dichloromethane (DCM) and acetonitrile were all purchased from Fisher 
Scientific. Tween-80 was provided by Firma Chempur Company. Methanol was obtained from 
Fisher Scientific Corporation. Phosphate buffered saline (PBS, pH7.4) was prepared in the 
laboratory from sodium chloride (NaCl), potassium chloride (KCl), disodium phosphate 
(Na2HPO4) and potassium dihydrogen phosphate (KH2PO4). All solvents used in this research 
study were high-performance liquid chromatography (HPLC) grade. All chemicals were used 
without further purification. Ultrapure water was prepared by a Milli-Q Plus System (Millipore 
Corporation). Amicon ultra-15 centrifugal filter units (molecular weight cut-off (MWCO): 100K) 
were purchased from Merck Millipore. 
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1.2. Preparation of docetaxel-loaded TPGS micelle (TPD), coumarin-6 loaded TPGS micelle   
       (TPC6) and TPDC6 micelle 
TPD and TPC6 micelles were prepared by solvent casting method. Briefly, docetaxel or 
coumarin-6 (2 mg) and 100 mg of TPGS were dissolved in 5 mL of chloroform solution and 
evaporated using rotary vacuum evaporator at 20°C-30°C until a thin film of drug-dispersed TPGS 
was formed. The thin film was then suspended in 10 mL of PBS buffer solution (pH 7.4) and 
incubated in an orbital water bath shaker at 37°C under constant agitation for 1.5 h, followed by 10 
min of sonication. The resultant mixture was filtered through a 0.22-μm filter and followed by 
centrifugal filter units with MWCO 100 kDa (Amicon ultra-15 ml) to separate the excess non-
incorporated drug precipitate from the suspension. The resultant suspension was then freezed at -
80°C and followed by further dried in a freeze-dryer for overnight for 12 hrs. The same procedure 
was used for the synthesis of TPDC6 micelle with the replacement of 2.0 mg of docetaxel and 0.2 
mg of coumarin-6 (10:1 weight ratio) and 100.0 mg of TPGS in 10 mL suspension.  
 
1.3. Particle size and size distribution of micelles 
The particle Size and size distribution of the TPD, TPC6 and TPDC6 micelles were 
measured by photon correlation spectroscopy (PCS) using Zetasizer (Nano ZS, Malvern Instrument 
Ltd, Malvern, UK). The micelle samples were first prepared by diluting the nanocarriers 
suspension with ultrapure water to a count rate of 300-500 kilo counts per second (kcps) and then 
sonicated for 5 min before measurement to ensure that the micelles were well dispersed [12]. All 
the measurements were recorded in triplicates (n±S.D). 
  
1.4. Drug loading and encapsulation efficiency  
The amount of docetaxel encapsulated in TPDC6 and TPD micelles was measured by high-
performance liquid chromatography (HPLC, Agilent LC1100, Agilent, Tokyo, Japan) in a reverse-
phase column (Eclipse XDB-C18, 4.6 x 250 mm, 5µm). Briefly, 1 mL of micelles was freeze-dried 
and dissolved in 1 mL of DCM to break the polymer matrix. After evaporating the DCM overnight, 
0.5 mL of mobile phase (50:50 % v/v acetonitrile and ultrapure water) was added to dissolve the 
extracted drugs. After centrifugation at 13,000 rpm for 5 min, a supernatant of the suspension was 
collected and the solution was then filtered through a 0.45 μm PVDF syringe filter before being 
transferred into an HPLC vial for HPLC analysis. The drug encapsulation efficiency was defined 
as the ratio between the amount of docetaxel encapsulated in the micelles and that added in the 
micelles preparation process. The drug loading was calculated as the weight of the drug 
encapsulated in the micelles divided by the total weight of the micelles [13, 14]. The drug loading 
and encapsulation efficiency of coumarin-6 encapsulated in TPDC6 and TPC6 micelles were 
determined by ultraviolet/visible (UV-VIS) spectrophotometer (Hitachi, U-1800) at 430 nm. 1 mL 
of methanol was added into a designated amount of freeze-dried micelle sample that was then 
vortexed until all freeze-dried micelle dissolved completely. The concentration of coumarin-6 in 
the micelle was detected by the UV-VIS spectrophotometer and the total amount of encapsulated 
coumarin-6 was calculated. All the measurements were recorded in triplicates (n±S.D). 
 
𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠
 × 100%             𝐸𝑞𝑢. (1) 
 𝐷𝑟𝑢𝑔 𝐸𝑛𝑡𝑟𝑎𝑝𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑛𝑒𝑐𝑦  =  
mass of drug in nanoparticles 
mass of drug used in formulation
 × 100%         𝐸𝑞𝑢. (2) 
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1.5. In vitro drug release profile 
The centrifugal ultrafiltration technique was used to study the in vitro drug release profile of 
docetaxel and coumarin-6 from micelles. One mL solutions of TPD, TPC6 and TPDC6 micelles 
were respectively added into the ultrafiltration membrane of centrifugal filter units with MWCO 10 
kDa and immersed in 30 mL of PBS (0.1 M, neutral pH 7.4) containing 0.1% (v/v) Tween-80 in 
the filtrate collection cup of centrifugal filter unit to simulate the sink condition. The entire system 
was kept at 37
o
C with gentle and constant shaking. At designated time intervals i.e. every 24
th
 hr, 
the incubation buffer was collected 1ml and replaced by a fresh incubation buffer. The collected 
incubation buffer, containing the released drug, was then freeze-dried and dissolved in DCM. The 
samples were filtered through 0.45 mm syringe filter before transferred into HPLC vial. The 
amount of docetaxel released was determined by HPLC method whereas the amount of coumarin-6 
released was determined by UV-VIS spectrophotometer as described in the protocols of drug 
loading and encapsulation determination (section 2.4). The drug release profiles were calculated 
accordingly [12,14]. All the measurement was recorded in triplicates (n±S.D). 
 
 
II. RESULT AND DISCUSSION 
 
2.1 Micelle particle size analysis 
The particle size of micelles measured by the dynamic light scattering (DLS) are shown in      
Figure 2, from which it can found that the mean micellar size (average) of the TPD, TPC6 and 
TPDC6 were 21.36±0.17 nm, 69.06±0.89 nm and 79.59±0.57 nm respectively, which were in a 
very favourable range of size for drug delivery in cancer treatment. It was revealed that micellar 
size typically in the range of 10 nm to 100 nm are appropriate for drug delivery in cancer diagnosis 
and therapy due to the reason of micelles in such size enhances EPR effect to a solid tumour 
[14,15]. The EPR phenomenon is based on the nanometer size range of micelles, leaky vasculature 
and impaired lymphatic drainage characteristics of the neoplastic tissues, which allowed the small 
size micelles (less than 100 nm) to participate in the extravasation through the fenestrations in 
tumour vessels and accumulate in the neoplastic tissues [16, 17]. According to Taurin et al. 
hydrodynamic diameter of more than 7 nm was able to escape from renal filtration and urinary 
excretion, leading to exhibit prolonged circulatory half-life in the blood and permit the 
accumulation of the nanocarriers within the neoplastic tissues. Therefore, TPD, TPC6 and TPDC6 
micelles developed in this research (figure.1) could be excellent delivery tools in cancer treatment 
due to the micelles size of less than 100 nm [18]. 
 
                                                                          
                                    (a)                              (b)                            (c)  
  
Figure 1:  The produced nanocarriers (a) TPD (b) TPC6 (c) TPDC6 
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Figure 2: Average particle size of the micelles. (A) TPD (B) TPC6 and (C) TPDC6 
2.2 Drug loading and encapsulation efficiency 
Drug load is determined as the weight of the drug (µg) per mg of the drug-loaded micelles. 
The results are shown in Table 1 and Table 2. The docetaxel load for TPD and TPDC6 micelles at 
16.28±1.34 % and 15.46±1.02 % respectively, while the drug loading of coumarin-6 for TPC6 and 
TPDC6 micelles are 10.60±0.89 % and 9.83±0.73 % respectively. The drug encapsulation 
efficiency of TPD micelles was 83.02±1.97% whereas the dye encapsulation efficiency of TPC6 
micelles was 54.05±1.31%. The data are in close agreement with the research carried out by Muthu 
and group for similar systems. Similarly, the drug encapsulation efficiency and dye encapsulation 
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efficiency of TPDC6 micelles were 78.99±1.26% and 36.20±0.89% for docetaxel and coumarin-6 
respectively [19].  
The drug loading of coumarin-6 for both TPC6 micelles and TPDC6 micelles were lower 
compared to docetaxel loading, yet, it was high enough for in vivo tracking of nanocarriers and 
imaging purpose [20]. The possibility for lower drug loading might be due to leakage of coumarin-
6 and docetaxel during the incubation step. Furthermore, the relatively lower drug loading and 
encapsulation efficiency of coumarin-6 for TPDC6 micelles could be caused by the difference in 
hydrophobicity between docetaxel and coumarin-6. According to the study done by  Huang et al, 
coumarin-6 being more hydrophilic than docetaxel [21], however, Mi and group claimed that drug 
solubilization was more effective for the most hydrophobic drug than for more hydrophilic ones, 
hence, it caused lower drug loading and encapsulation for coumarin-6 in TPDC6 micelles [22]. 
Moreover, the higher amount of docetaxel (2 mg) compared to coumarin-6 (0.2 mg) in the micelles 
preparation process might be one of the reason. The weight ratio of 10:1 and drug load of 
15.46±1.02 %: 9.83±0.76 % for docetaxel and coumarin-6 respectively were adequate for the 
therapy purpose by docetaxel and imaging purpose by coumarin-6. 
 
Table 1: Drug loading and encapsulation efficiency of docetaxel in TPD and TPDC6 micelles 
 
Micelles Drug load % Encapsulation efficiency (%) 
TPD 16.28±1.34 83.02±1.97 
TPDC6 15.46±1.02 78.99±1.26 
 
Table 2: Drug loading and encapsulation efficiency of coumarin-6 in TPC6 and TPDC6 micelles 
 
Micelles Drug load (%) Encapsulation efficiency (%) 
TPC6 10.60±0.89 54.05±1.31 
TPDC6 9.83±0.73 36.20±0.89 
 
 
 
 
2.3 In vitro drug release profile 
In order to facilitate passive targeting to the tumour site, the drug should be released in a 
controlled manner and obtained sustained circulation to attain sustained therapeutic efficacy. In 
vitro release study was carried out in PBS pH 7.4 with 0.1% v/v Tween-80 and immediately 
replaced by the fresh buffer for simulating the sink condition. Figure 3 and 4 show the in vitro drug 
release profiles of docetaxel and coumarin-6 respectively, in TPD, TPC6 and TPDC6 micelles for 
240 hours. It can be seen from the figures that the drug release profile of the three micelle systems 
follows a biphasic pattern with an initial burst release followed by controlled release. The initial 
burst of docetaxel release was 55.25±1.88% and 21.62±0.36% in the first 50 hours, for the TPD 
and TPDC6 micelles respectively. Whereas, the initial burst of coumarin-6 was 16.30±0.53% and 
10.70±0.46% in the first 48 hours, for the TPC6 and TPDC6 micelles respectively. The burst 
release could be due to the drug poorly encapsulated in the polymeric core and located under the 
periphery of the nanocarriers while the sustained release was attributed to the diffusion of the well-
entrapped drug in the core of nanocarriers [23]. 
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After 10 days, the accumulative docetaxel drug release from TPD micelles achieved 64.99±2.12%, 
which was significantly higher than that from TPDC6 micelles with only 38.88±1.81% drug 
release. This might be due to the diffusivity of drug which depends on its solubility [24].  As 
discussed previously, coumarin-6 is more hydrophilic than docetaxel and this might have affected 
the diffusivity and drug release of docetaxel in TPDC6 micelles. Besides, Reza et al revealed that 
the mechanisms of drug release were changed with the content in the polymer could be one of the 
reasons for this phenomenon [25]. Whereas, no significant differences were observed for the 
accumulative coumarin-6 drug release from TPC6 and TPDC6 micelles after 10 days, which were 
21.63±0.21% and 16.86±0.96% respectively. The fluorescence probe coumarin-6 encapsulated 
within the nanocarriers was acting as tracers in vivo or in vitro due to their relatively low leak from 
nanocarriers and good sensitivity. The very low release of coumarin-6 from micelles indicated that 
coumarin-6 could be adequate fluorescence probes for micelles behaviour in vivo, and the 
fluorescence signals detected in the cells or tissue are well represented the distribution of the 
micelles instead of from release of coumarin-6 from the micelles into the medium [26]. 
All three micelle systems showed a sustained and controlled drug release, which implies that 
the drugs can be released slowly and kept for a long period both in vivo and in vitro. This leads to 
avoiding the repeated administrations and eventually less drug accumulation and toxic effects in 
the body [ 27, 28]. 
 
 
Figure 3: In vitro accumulative docetaxel drug release of TPD and TPDC6 micelles at pH7.4 
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Figure 4: In vitro accumulative coumarin-6 drug release of TPC6 and TPDC6 micelles at pH7.4 
 
III. CONCLUSION 
 
In summary, a dual modality system was successfully developed using TPGS micelles for the 
sustainable and controlled delivery of docetaxel and coumarin-6 into the cancer cells. This research 
proved that the solvent casting method is considered suitable for the preparation of micelles with 
co-delivery of therapeutic and diagnostic agents. The DLS and particle size analyser showed that 
the TPDC6 micelles have an average size of 79.59±0.57 nm in diameter. Drug loading up to 
15.46±1.02 % (encapsulation efficiency of 78.99±1.26%) and 9.83±0.76 % (encapsulation 
efficiency of 36.20±0.89%) for docetaxel and coumarin-6 respectively. These results are adequate 
for the purposes of therapy and diagnosis on cancer cells by docetaxel and coumarin-6 
respectively. In vitro, drug release profiles demonstrated a desired sustained and controlled drug 
release pattern of the micelles which have advantages of less frequent drug administration, 
maximum utilization of drug and reduction in the side effect of the drug in the body. 
There are few recommendations that should be considered for further study and 
investigation in order to improve the results from this research. From this study, the drug loading 
and encapsulation efficiency of the dual-modality micelles (TPDC6 micelles) is not in the most 
excellent condition, hence, it is recommended to optimise the drug loading by varying the weight 
ratio of docetaxel, coumarin-6 and TPGS or change a different preparation method to develop the 
micelles in order to produce a smaller size micelles with higher drug loading and encapsulation 
efficiency which would be very beneficial in drug delivery. Besides, the drug release profile of 
TPDC6 micelles in this study showed that the docetaxel drug release was slower and lower 
compared to TPD micelles. Therefore, further investigation on shape and surface morphology on 
the micelles could be conducted in order to understand the drug release mechanisms of TPDC6 
micelles. 
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